Compare Supplements

Approved breast-cancer dose is 1 mg once daily. Off-label use in men mirrors this (typically 0.5–1 mg/day or 1 mg 2–3×/week to avoid over-suppressing estradiol) under a clinician, with estradiol and bone monitoring. A prescription drug; not an approved men's-health regimen.

Any time

Oral tablet (anastrozole)

Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.

Any time

Oral letrozole 2.5 mg tablet (Femara / generic)

• Premenopausal women / pregnancy (teratogenic; approved only postmenopausal)
• Pre-existing osteoporosis or high fracture risk (estrogen suppression worsens bone)
• Severe hepatic impairment

• Tamoxifen / estrogen-containing therapies
• Bisphosphonates / bone agents

• Pregnancy (teratogenic risk) — used to induce ovulation, but stopped once pregnancy occurs
• Premenopausal women for breast-cancer indication without ovarian suppression
• Hypersensitivity to letrozole

• Tamoxifen / other estrogen-modulating agents
• Exogenous estrogen / hormone therapy
• Exogenous testosterone / anabolic steroids